The company has received a communication from the US Food and Drug Administration (USFDA), classifying the inspection conducted at its Goa facility between January 28 to February 8, 2019 as Official Action Indicated (OAI)... The inspection at the Goa facility had closed with two observations, Lupin said in a regulatory filing.
from Moneycontrol http://bit.ly/2Mb9ucY
No comments:
Post a Comment